BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36657940)

  • 21. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.
    Zhang Y; Suo SS; Yang HJ; Zhou XP; You LS; Yu WJ; Wang ZM; Jin J
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):357-365. PubMed ID: 31938902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in Castleman Disease.
    Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
    Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity?
    Masaki Y; Nakajima A; Iwao H; Kurose N; Sato T; Nakamura T; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Fukushima T; Okazaki T; Umehara H
    J Clin Exp Hematop; 2013; 53(1):79-85. PubMed ID: 23801138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
    Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
    PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-associated multicentric Castleman disease: a report of 19 cases at an oncology institution.
    Volkow-Fernández P; Lome-Maldonado C; Quintero-Buenrostro H; Islas-Muñoz B; Cornejo-Juárez P
    Int J STD AIDS; 2020 Mar; 31(4):318-325. PubMed ID: 32089093
    [No Abstract]   [Full Text] [Related]  

  • 27. A Rare Lymphoproliferative Disease: Castleman Disease.
    Gündüz E; Özdemir N; Bakanay ŞM; Karakuş S
    Turk J Haematol; 2021 Dec; 38(4):314-320. PubMed ID: 34719151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
    van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
    Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does Kaposi's sarcoma predict multicentric Castleman disease in the presence of generalized lymphadenopathy?
    Alkaied H; Harris K; Elsayegh D; Khachaturova I; Awasum M; Varma S
    Med Oncol; 2012 Jun; 29(2):1109-13. PubMed ID: 21472488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.
    Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D
    Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study.
    Yu T; Cai QQ; Zhai QL; Li L; Fang X; Li J; Sun R; Yang H; Wang Z; Qian W; Xu-Monette ZY; Young KH; Yu L
    Leuk Lymphoma; 2022 Dec; 63(13):3082-3091. PubMed ID: 36074798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology of Castleman Disease.
    Simpson D
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):1-10. PubMed ID: 29157611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
    Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y
    Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study.
    Sopfe J; Endres A; Campbell K; Hayes K; Trout AT; Liang X; Lorsbach R; O'Brien MM; Cost CR
    Pediatr Blood Cancer; 2019 May; 66(5):e27613. PubMed ID: 30680887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
    Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
    Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Castleman Disease Pathogenesis.
    Fajgenbaum DC; Shilling D
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):11-21. PubMed ID: 29157613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012).
    Kawabata H; Takai K; Kojima M; Nakamura N; Aoki S; Nakamura S; Kinoshita T; Masaki Y
    J Clin Exp Hematop; 2013; 53(1):57-61. PubMed ID: 23801135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans.
    Chorzelski T; Hashimoto T; Maciejewska B; Amagai M; Anhalt GJ; Jablonska S
    J Am Acad Dermatol; 1999 Sep; 41(3 Pt 1):393-400. PubMed ID: 10459112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
    Melikyan AL; Egorova EK; Julhakyan HL; Kovrigina AL; Savchenko VG
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S159-65. PubMed ID: 27133959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.